Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS G12D Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)

Summary

The purpose of this phase II trial is to evaluate the safety and efficacy of Vemurafenib and Sorafenib in patients KRAS G12D mutated pancreatic cancer who have progressed on standard of care chemotherapy.

General Information

NCT#: NCT05068752
Study ID: HRI-Vemurafenib-Sorafenib
Trial Phase: Phase II

Trial Sponsor: HonorHealth Research Institute
Therapies Used in This Trial: Sorafenib, Vemurafenib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search